Jan. 5, 2012

Birmingham, AL- Novartis, the drug company that makes Tekturna has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also at high risk of cardiovascular and renal events after researchers saw an increased number of adverse events–including nonfatal stroke, renal complications, hyperkalemia and hypotension–in the Tekturna plus standard of care arm.

Novartis has stated that it will cease promotion of Rasilez/Tekturna-based products for use in combination with an ACE inhibitor or angiotensin receptor blocker.

If you believe that you have suffered unusual side effects after using Tekturna™ and you would like to have a Lawyer view the facts of your case please feel free to contact us at the number and email address below.

E. Nathan Harris, Esq., Founding Member
The Harris Law Firm